Use of A-ring aromatic acetyl minocycline and pharmaceutical preparations derived from same for treatment and prevention of inflammation, autoimmune disorders and rejection of transplants

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses the use of A-ring aromatized acetyl minocycline derivatives, especially pentaacetylminocycline, as pharmaceutical agents for the treatment and prevention of T cell-mediated diseases. These compounds show a potent immunosuppressive effect by specifically inhibiting T cell proliferation and cytokine production, making them effective in treating inflammatory conditions, autoimmune disorders, allergies, and transplant rejection without the antibiotic activity or side effects commonly seen with traditional minocycline.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapy for autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, lupus, and type 1 diabetes
• Treatment of T cell-mediated allergies, including allergic rhinitis and asthma
• Prevention and treatment of transplant rejection (organ transplantation)
• Control of inflammatory diseases involving T-cell activity
• Development of novel immunosuppressive pharmaceuticals for human or veterinary medicine

BenefitsContent extracted from patent full text and abstract with AI.

• Selective suppression of T cell-mediated immune responses, minimizing broad immunosuppression
• Fewer side effects compared to traditional minocycline, particularly reduced liver toxicity and risk of drug-induced autoimmune reactions
• No antibiotic activity, eliminating concerns around antibiotic resistance development
• Shows effectiveness at lower concentrations with fast-acting therapeutic effects
• Broad applicability across multiple immune-mediated diseases and routes of administration (oral, intravenous, topical, etc.)

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Use of A-ring aromatized acetyl minocycline compounds (I) for treating T cell-mediated diseases, is claimed. Use of A-ring aromatized acetyl minocycline compounds of formula (I) for treating T cell-mediated diseases, is claimed. R1-R5 : acetyl or H, where at least one of R1-R5 is acetyl. An independent claimS included for a pharmaceutical composition comprising A-ring aromatized acetyl minocycline compounds (I) and a pharmaceutical acceptable carrier. [Image] ACTIVITY : Antiallergic; Immunosuppressive. Test details are described but no results for the compounds of the claims are given. MECHANISM OF ACTION : None given.